CD44-specific short peptide A6 boosts cellular uptake and anticancer efficacy of PEGylated liposomal doxorubicin in vitro and in vivo
Abstract Although liposomes have improved patient safety and the pharmacokinetic profile of free drugs, their therapeutic efficacy has only shown marginal improvement. The incorporation of active-targeted ligands to enhance cellular uptake has shown promise in preclinical studies. However, no active...
Main Authors: | Rezvan Yazdian-Robati, Ehsan Amiri, Hossein Kamali, Aysun Khosravi, Seyed Mohammad Taghdisi, Mahmoud Reza Jaafari, Mohammad Mashreghi, Seyedeh Alia Moosavian |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-11-01
|
Series: | Cancer Nanotechnology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12645-023-00236-0 |
Similar Items
-
Anti-Epcam Aptamer (Syl3c)-Functionalized Liposome for Targeted Delivery Of Doxorubicin: In Vitro And In Vivo Antitumor Studies in Mice Bearing C26 Colon Carcinoma
by: Mohammad Mashreghi, et al.
Published: (2020-05-01) -
The role of size in PEGylated liposomal doxorubicin biodistribution and anti‐tumour activity
by: Saba Dadpour, et al.
Published: (2022-09-01) -
Chemotherapeutic activity of Silymarin combined with doxorubicin liposomes in 4T1 breast cancer cells
by: Fatemeh Gheybi, et al.
Published: (2019-02-01) -
Neoadjuvant Combination Chemotherapy with Pegylated Liposomal Doxorubicin and Vinorelbine for Locally Advanced Breast Cancer
by: Zhen-zhou SHEN, et al.
Published: (2010-02-01) -
Harnessing Nanomedicine to Potentiate the Chemo-Immunotherapeutic Effects of Doxorubicin and Alendronate Co-Encapsulated in Pegylated Liposomes
by: Alberto Gabizon, et al.
Published: (2023-11-01)